Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014186 | 1.00 | OPRL1 (0.51) | OPRL1TOP2AFKBP1ANSD2HRH1 | |
| SCHEMBL2877475 | 0.80 | OPRL1 (0.41) | OPRL1NSD2HTR1AHTR2ADRD2 | |
| SCHEMBL13000023 | 0.78 | OPRL1 (0.48) | OPRL1NSD2HRH1HTR1AHTR2A | |
| SCHEMBL2885507 | 0.76 | OPRL1 (0.54) | OPRL1NSD2HRH1HTR1AHTR2A | |
| SCHEMBL2880712 | 0.74 | OPRL1 (0.37) | OPRL1 | |
| SCHEMBL12975879 | 0.74 | OPRL1 (0.37) | OPRL1 | |
| SCHEMBL12975884 | 0.74 | OPRL1 (0.48) | OPRL1HRH1DRD2 | |
| SCHEMBL30106079 | 0.72 | FKBP1A (0.37) | TOP2AFKBP1ADUT | |
| SCHEMBL9606663 | 0.72 | FKBP1A (0.37) | TOP2AFKBP1ADUT | |
| SCHEMBL420855 | 0.72 | FKBP1A (0.37) | TOP2AFKBP1ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885TOP2A 4669/4885FKBP1A 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.